Nobody does, but guesses generally range from about the start of 2025 to the end of 2026. You cannot predict how fast an experimental drug in a medical trial will have willing patients signing up that meet the inclusion criterea.
There is also the chance of an early termination of the trial due to either supreme efficacy being demonstrated, or the level of efficacy reaching a point where it is impossible to achieve the minimum efficacy level possible. That could occur next year (in 2024)
The other issue is we have no idea how many patients will be in this trial. The bigger the number is, the longer the trial will take to recruit and complete 12 month follow up.
So lots of variables in the equation.
If approved the annual income likely in the billions, and right now company valued around 1.2 billion by SP market capitalisation.
Nobody does, but guesses generally range from about the start of...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
-0.040(3.54%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.14 | $1.09 | $10.61M | 9.616M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 241716 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.10 |
Change
-0.040 ( 3.00 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.14 | $1.09 | 1809171 | ||
| Last updated 15.59pm 09/05/2024 ? | |||||
| MSB (ASX) Chart |